侵袭性热带念珠菌感染流行病学及药物敏感性

摘要/Abstract

摘要： 全球范围内,随着抗肿瘤药物、免疫抑制剂和广谱抗菌药物的使用,真菌感染的发病率显著提高,其中念珠菌感染占到绝大多数。目前热带念珠菌已经成为非白念珠菌中最常见的病原菌。我国热带念珠菌的临床分离率及对氟康唑及伏立康唑的耐药率都明显高于世界平均水平。但是,相比于白念珠菌,关于热带念珠菌的研究及相关临床信息相对较少。该文就侵袭性热带念珠菌感染危险因素、流行病学以及药物敏感性进行全面的综述。

关键词: 热带念珠菌, 流行病学, 抗真菌药物敏感性

Abstract: With the using of antineoplastic, immunosuppressive and broad-spectrum antimicrobial agents, the incidence of fungal infections climbed significantly, most of which were caused by Candida species.Candida tropicalis has become the commonest pathogenic non-albicans Candida species.In China, the prevalence of C.tropicalis and its resistant rate to fluconazole and voriconazole were much higher than worldwide average level.However, comparing to Candida albicans, researching and related clinical information about C.tropicalis was insufficient.Therefore, the aim of the present article was to have a comprehensive and systematic review of the risk factors of invasive C.tropicalis infection, epidemiology and antifungal resistance.

Key words: Candida tropicalis, epidemiology, antifungal susceptibility

中图分类号:

R519.3

范欣, 徐英春. 侵袭性热带念珠菌感染流行病学及药物敏感性[J]. 中国真菌学杂志, 2014, 9(6): 368-372.

FAN Xin, XU Ying-chun. Epidemiology and antifungal susceptibility of invasive Candida tropicalis[J]. Chinese Journal of Mycology, 2014, 9(6): 368-372.

参考文献

[1] Miceli MH,Diaz JA,Lee SA.Emerging opportunistic yeast infections[J].Lancet Infect Dis,2011,11 (2):142-151.
[2] Kothari A,Sagar V.Epidemiology of Candida bloodstream infections in a tertiary care institute in India[J].Indian J Med Microbiol,2009,27 (2):171-172.
[3] Verma AK,Prasad KN,Singh M,et al.Candidaemia in patients of a tertiary health care hospital from north India[J].Indian J Med Res,2003,117:122-128.
[4] Yang SP,Chen YY,Hsu HS,et al.A risk factor analysis of healthcare-associated fungal infections in an intensive care unit:a retrospective cohort study[J].BMC Infect Dis,2013,13:10.
[5] Cisterna R,Ezpeleta G,Telleria O,et al.Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain[J].J Clin Microbiol,2010,48 (11):4200-4206.
[6] Nucci M,Queiroz-Telles F,Tobon AM,et al.Epidemiology of opportunistic fungal infections in Latin America[J].Clin Infect Dis,2010,51 (5):561-570.
[7] Achkar JM,Fries BC.Candida infections of the genitourinary tract[J].Clin Microbiol Rev,2010,23 (2):253-273.
[8] Tumbarello M,Posteraro B,Trecarichi EM,et al.Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia[J].J Clin Microbiol,2007,45 (6):1843-1850.
[9] Bizerra FC,Nakamura CV,de Poersch C,et al.Characteristics of biofilm formation by Candida tropicalis and antifungal resistance[J].FEMS Yeast Res,2008,8 (3):442-450.
[10] Silva S,Henriques M,Oliveira R,et al.In vitro biofilm activity of non-Candida albicans Candida species[J].Curr Microbiol,2010,61 (6):534-540.
[11] Paul N,Mathai E,Abraham OC,et al.Factors associated with candiduria and related mortality[J].J Infect,2007,55 (5):450-455.
[12] Binelli CA,Moretti ML,Assis RS,et al.Investigation of the possible association between nosocomial candiduria and candidaemia[J].Clin Microbiol Infect,2006,12 (6):538-543.
[13] Munoz P,Giannella M,Fanciulli C,et al.Candida tropicalis fungaemia:incidence,risk factors and mortality in a general hospital[J].Clin Microbiol Infect,2011,17 (10):1538-1545.
[14] Kothavade RJ,Kura MM,Valand AG,et al.Candida tropicalis:its prevalence,pathogenicity and increasing resistance to fluconazole[J].J Med Microbiol,2010,59 (Pt 8):873-880.
[15] Pfaller MA,Diekema DJ.Epidemiology of invasive candidiasis:a persistent public health problem[J].Clin Microbiol Rev,2007,20 (1):133-163.
[16] Pfaller MA,Diekema DJ,Gibbs DL,et al.Results from the ARTEMIS DISK Global Antifungal Surveillance Study,1997 to 2007:a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion[J].J Clin Microbiol,2010,48 (4):1366-1377.
[17] Pfaller MA,Castanheira M,Messer SA,et al.Echinocandin and triazole antifungal susceptibility profiles for Candida spp.,Cryptococcus neoformans,and Aspergillus fumigatus:application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)[J].Diagn Microbiol Infect Dis,2011,69 (1):45-50.
[18] Chai LY,Denning DW,Warn P.Candida tropicalis in human disease[J].Crit Rev Microbiol,2010,36 (4):282-298.
[19] Tan TY,Tan AL,Tee NW,et al.The increased role of non-albicans species in candidaemia:results from a 3-year surveillance study[J].Mycoses,2010,53 (6):515-521.
[20] Chakrabarti A,Chatterjee SS,Rao KL,et al.Recent experience with fungaemia:change in species distribution and azole resistance[J].Scand J Infect Dis,2009,41 (4):275-284.
[21] Nucci M,Colombo AL.Candidemia due to Candida tropicalis:clinical,epidemiologic,and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals[J].Diagn Microbiol Infect Dis,2007,58 (1):77-82.
[22] Liu W,Tan J,Sun J et al.Invasive candidiasis in intensive care units in China:in vitro antifungal susceptibility in the China-SCAN study[J].J Antimicrob Chemother,2014,69 (1):162-167.
[23] Wang H,Xiao M,Chen SC,et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J].J Clin Microbiol,2012,50 (12):3952-3959.
[24] Casalinuovo IA,Di Francesco P,Garaci E.Fluconazole resistance in Candida albicans:a review of mechanisms[J].Eur Rev Med Pharmacol Sci,2004,8 (2):69-77.
[25] Barchiesi F,Calabrese D,Sanglard D,et al.Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750[J].Antimicrob Agents Chemother,2000,44 (6):1578-1584.
[26] Garcia-Effron G,Chua DJ,Tomada JR,et al.Novel FKS mutations associated with echinocandin resistance in Candida species[J].Antimicrob Agents Chemother,2010,54 (5):2225-2227.
[27] Pfaller MA,Andes D,Arendrup MC,et al.Clinical breakpoints for voriconazole and Candida spp.revisited:review of microbiologic,molecular,pharmacodynamic,and clinical data as they pertain to the development of species-specific interpretive criteria[J].Diagn Microbiol Infect Dis,2011,70 (3):330-343.
[28] Pfaller MA,Andes D,Diekema DJ,et al.Wild-type MIC distributions,epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida:time for harmonization of CLSI and EUCAST broth microdilution methods[J].Drug Resist Updat,2010,13 (6):180-195.